Cargando…
Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments
BACKGROUND: The immunotherapy strategy for autoimmune encephalitis is based on several types and schedules of both first- and second-line drugs. Failing to respond to the latter prompts the use of non-conventional rescue therapies, with higher risks of severe adverse effects. We report on a protocol...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616745/ https://www.ncbi.nlm.nih.gov/pubmed/35953578 http://dx.doi.org/10.1007/s10072-022-06313-3 |